Table 3 Main neurological findings in the recall cohort by symptom group.
From: Use of Estonian Biobank data and participant recall to improve Wilson’s disease management
Neurological trait | Count of affected individuals (out of 15) | Proportion (%) |
|---|---|---|
Tremors | 10 | 66.7 |
Action tremor | 4 | 26.7 |
Postural tremor | 10 | 66.7 |
Task-specific tremor - handwriting | 2 | 13.3 |
Task-specific tremor - speaking | 1 | 6.7 |
Rest tremor | 1 | 6.7 |
Oropharyngeal movement disorders | 8 | 53.3 |
Dysarthria | 8 | 53.3 |
Dysphagia | 4 | 26.7 |
Hypersalivation | 5 | 33.3 |
Ataxias | 6 | 40 |
Sensory ataxia | 2 | 13.3 |
Static ataxia | 3 | 20 |
Dynamic ataxia | 4 | 26.7 |
Other extrapyramidal movement disorders | 5 | 33.3 |
Dystonia | 2 | 13.3 |
Rigidity | 3 | 20 |
Bradykinesia | 3 | 20 |
Choreathetosis | 1 | 6.7 |
Spasticity | 2 | 13.3 |
Epilepsy | 0 | 0 |
Earlier diagnosis of cognitive impairment | 0 | 0 |
Mood disorders | 3 | 20 |
Depression | 3 | 20 |
Mania | 1 | 6.7 |
Impairment of attention | 1 | 6.7 |
MRI findings | ||
MRI: midbrain atrophy | 1 | 6.7 |
MRI: microangiopathic foci | 5 | 33.3 |
MRI: hyperintense T2/FLAIR signals | 9 | 60 |
MRI: no findings | 3 | 20 |
Transcranial sonography (TCS) findings | ||
Hyperechogenicity of the lentiform nucleus (LN + ) | 11 | 73.3 |
LN+ bilaterality | 7 | 46.7 |
